Patents by Inventor Xiuwen Zhu

Xiuwen Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12286427
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.
    Type: Grant
    Filed: July 19, 2024
    Date of Patent: April 29, 2025
    Assignee: Kumquat Biosciences Inc.
    Inventors: Yi Liu, Pingda Ren, Liansheng Li, Zhimin Zhu, Xiuwen Zhu
  • Publication number: 20250074874
    Abstract: The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.
    Type: Application
    Filed: November 15, 2024
    Publication date: March 6, 2025
    Applicant: Arena Pharmaceuticals, Inc.
    Inventors: Robert M. Jones, Daniel J. Buzard, Sangdon Han, Sun Hee Kim, Juerg Lehmann, Brett Ullman, Jeanne V. Moody, Xiuwen Zhu, Scott Stirn
  • Patent number: 12209102
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.
    Type: Grant
    Filed: May 17, 2024
    Date of Patent: January 28, 2025
    Assignee: Kumquat Biosciences Inc.
    Inventors: Pingda Ren, Liansheng Li, Baogen Wu, Xiaoming Li, Zhiyong Chen, Siling Zhao, Yi Liu, Xiuwen Zhu
  • Publication number: 20240425522
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.
    Type: Application
    Filed: May 17, 2024
    Publication date: December 26, 2024
    Inventors: Pingda Ren, Liansheng Li, Baogen Wu, Xiaoming Li, Zhiyong Chen, Siling Zhao, Yi Liu, Xiuwen Zhu
  • Publication number: 20240425525
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.
    Type: Application
    Filed: July 29, 2024
    Publication date: December 26, 2024
    Inventors: Pingda Ren, Liansheng Li, Baogen Wu, Xiaoming Li, Zhiyong Chen, Siling Zhao, Yi Liu, Xiuwen Zhu
  • Publication number: 20240398828
    Abstract: The present disclosure provides compounds and pharmaceutical compositions comprising the same. The compounds, pharmaceutical compositions thereof, and methods of using the same have a range of utilities as therapeutics, diagnostics, and research tools. The subject compositions and methods are particularly useful for potentiating immune response and/or applicable for treating cancer and other diseases.
    Type: Application
    Filed: May 20, 2024
    Publication date: December 5, 2024
    Inventors: Liansheng Li, Xiuwen Zhu, Pingda Ren, Jonathan Deane, Lomon So, Yi Liu
  • Publication number: 20240383888
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.
    Type: Application
    Filed: July 19, 2024
    Publication date: November 21, 2024
    Inventors: Yi Liu, Pingda Ren, Liansheng Li, Zhimin Zhu, Xiuwen Zhu
  • Patent number: 12109219
    Abstract: Provided are certain methods useful in the treatment of cancer comprising administering a compound of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor;
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: October 8, 2024
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Jayant Thatte, Anthony C. Blackburn, Sangdon Han, Robert M. Jones, Jae-Kyu Jung, Antonio Garrido Montalban, Biman B. Pal, Jaimie Karyn Rueter, Sonja Strah-Pleynet, Lars Thoresen, Yifeng Xiong, Dawei Yue, Xiuwen Zhu
  • Publication number: 20240270736
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.
    Type: Application
    Filed: November 28, 2023
    Publication date: August 15, 2024
    Inventors: Baogen Wu, Liansheng Li, Pingda Ren, Zhiyong Chen, Siling Zhao, Xiuwen Zhu
  • Publication number: 20240254129
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.
    Type: Application
    Filed: August 8, 2023
    Publication date: August 1, 2024
    Inventors: Liansheng Li, Xiuwen Zhu, Zhimin Zhu, Pingda Ren, Yuan Liu, Yi Liu
  • Publication number: 20240166641
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.
    Type: Application
    Filed: September 7, 2023
    Publication date: May 23, 2024
    Inventors: Liansheng Li, Xiuwen Zhu, Pingda Ren, Jonathan Deane, Lomon So, Yi Liu
  • Publication number: 20230331717
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.
    Type: Application
    Filed: February 27, 2023
    Publication date: October 19, 2023
    Inventors: Yi Liu, Pingda Ren, Liansheng Li, Zhimin Zhu, Xiuwen Zhu
  • Patent number: 11771695
    Abstract: Provided are certain methods useful in the treatment of pain comprising administering a compound of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor;
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: October 3, 2023
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Jayant Thatte, Anthony C. Blackburn, Sangdon Han, Robert M. Jones, Jae-Kyu Jung, Antonio Garrido Montalban, Biman B. Pal, Jaimie Karyn Rueter, Sonja Strah-Pleynet, Lars Thoresen, Yifeng Xiong, Dawei Yue, Xiuwen Zhu
  • Patent number: 11746091
    Abstract: The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: September 5, 2023
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Robert M. Jones, Sangdon Han, Lars Thoresen, Jae-Kyu Jung, Sonja Strah-Pleynet, Xiuwen Zhu, Yifeng Xiong, Dawei Yue
  • Publication number: 20230257349
    Abstract: The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.
    Type: Application
    Filed: August 11, 2022
    Publication date: August 17, 2023
    Inventors: Robert M. Jones, Daniel J. Buzard, Sangdon Han, Sun Hee Kim, Juerg Lehmann, Brett Ullman, Jeanne V. Moody, Xiuwen Zhu, Scott Stirn
  • Patent number: 11608339
    Abstract: The present invention relates to compounds of Formula A and pharmaceutical compositions thereof that modulate the activity of the 5-HT2C receptor.
    Type: Grant
    Filed: October 19, 2020
    Date of Patent: March 21, 2023
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Graeme Semple, Albert S. Ren, Thomas O. Schrader, Michelle Kasem, Xiuwen Zhu
  • Publication number: 20220306586
    Abstract: The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor.
    Type: Application
    Filed: November 8, 2021
    Publication date: September 29, 2022
    Inventors: Robert M. Jones, Sangdon Han, Lars Thoresen, Jae-Kyu Jung, Sonja Strah-Pleynet, Xiuwen Zhu, Yifeng Xiong, Dawei Yue
  • Publication number: 20220241274
    Abstract: Provided are certain methods useful in the treatment of pain comprising administering a compound of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor;
    Type: Application
    Filed: September 17, 2021
    Publication date: August 4, 2022
    Inventors: Jayant Thatte, Anthony C. Blackburn, Sangdon Han, Robert M. Jones, Jae-Kyu Jung, Antonio Garrido Montalban, Biman B. Pal, Jaimie Karyn Rueter, Sonja Strah-Pleynet, Lars Thoresen, Yifeng Xiong, Dawei Yue, Xiuwen Zhu
  • Publication number: 20220073494
    Abstract: A compound having one of formula (1), formula (2), formula (3) and formula (4) or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: January 29, 2020
    Publication date: March 10, 2022
    Inventors: Shyama HERATH, Mariangela URBANO, Eun-Kyong KIM, Chixu CHEN, Qiang LI, Julia AYERS, Kaikoo NAKAMURA, Xiuwen ZHU, Hugh ROSEN, Jonathan S. ROSENBLUM, Melissa C. ZHANG, Yongsheng LIU, Masahiro UENO
  • Patent number: 11214548
    Abstract: The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: January 4, 2022
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Robert M. Jones, Sangdon Han, Lars Thoresen, Jae-Kyu Jung, Sonja Strah-Pleynet, Xiuwen Zhu, Yifeng Xiong, Dawei Yue